Patients treated with the blood thinner edoxaban for six months after a heart valve replacement procedure experienced fewer symptomless blood clots inside the heart valve replacement than patients who were treated with two antiplatelet drugs, according to data presented at the American College of Cardiology's 71st Annual Scientific Session.
The ADAPT-TAVR trial showed a numerical reduction in leaflet thrombosis with edoxaban versus dual antiplatelet therapy, but no reduction in cerebral events or neurocognitive function
Dr. Dong Zhao Announced as Deputy Editor of JACC: Asia
China-based physician scientist among prestigious representatives of cardiovascular health to serve on journal’s editorial board
Feb 08, 2021
WASHINGTON (Feb 08, 2021) -
Dong Zhao, MD, PhD, has been named a deputy editor of
JACC: Asia, the American College of Cardiology’s newest journal, which will feature original articles, cutting-edge technology manuscripts and clinical practice guidelines centered on Asian populations and by Asian authors.
A distinguished clinical epidemiologist, Zhao is currently a professor of preventive cardiology at the Beijing Institute of Heart, Lung and Blood Vessel Diseases (BIHLBD) at Beijing Anzhen Hospital, Capital Medical University. She is the former deputy director of BIHLBD. Zhao is also a member of several writing committees on China and international guidelines focused on preventive cardiology, dyslipidemia management and hypertension management.